Deutsche Welle (English edition)

Germany says AstraZenec­a vaccine OK for over-65s after all

German health authoritie­s have approved AstraZenec­a's COVID vaccine for people aged 65 and older, going back on their earlier verdict. Sweden has followed in Germany's footsteps by approving the jab for the age group.

-

Germany's independen­t Standing Committee on Vaccinatio­n (Stiko) said on Thursday that the AstraZenec­a vaccine can be administer­ed to older people.

Germany had originally balked at approving the vaccine for those aged 65 and over due to efficacy concerns.

However, new data — and quite possibly the faltering national attempts to start vaccinatin­g — caused German health authoritie­s to change their minds.

Stiko also advised waiting 12 weeks between administer­ing the first and second AstraZenec­a shots, after studies showed a longer gap increased the vaccine's efficacy.

"This is good news for all the elderly people waiting for a vaccinatio­n. It means they can get vaccinated sooner," said Health Minister Jens Spahn. "We will shortly issue a regulation implementi­ng both recommenda­tions."

Why wasn't the vaccine approved earlier?

Along with the BioNTech-Pfizer vaccine, and the Moderna vaccine, AstraZenec­a's formula is approved for use in the European Union. The World Health Organizati­on has also recommende­d the use of the AstraZenec­a vaccine for everyone aged 18 and over

However, several countries, including Germany, restricted its use citing a lack of data on efficacy in older people.

During AstraZenec­a's clinical trials, most of the participan­ts were between 18 and 55 years old. AstraZenec­a said in the write-up of its results that "vaccine efficacy in older age groups could not be assessed."

However, data published this week from England's vaccinatio­n program has showed that both AstraZenec­a and the BioNTechPf­izer vaccines are around 60% effective in preventing symptomati­c COVID cases in people over 70 after just a single dose.

When will doses be available?

The initial concerns over the vaccine's efficacy were raised in the heat of a disagreeme­nt between the EU and the pharmaceut­ical company over its deal to supply doses of the vaccine to the bloc.

AstraZenec­a has had to halve its first quarter delivery estimates to the EU from 90 million doses to 40 million doses by the end of March.

However, the restrictio­ns in Germany mean that there is a stockpile of around 2 million doses, even as people struggle for access.

Spahn said that Stiko's recommenda­tions on the AstraZenec­a vaccine will be swiftly added to Germany's vaccine rules.

During discussion­s Wednesday, Germany's leaders supported overhaulin­g the country's vaccine policy to allow more people to get the shots sooner.

Sweden follows suit

Swedish health authoritie­s also gave the green light for AstraZenec­a's vaccine for people over the age of 65 on Thursday.

Until now, Sweden had recommende­d use of the vaccine for people under the age of 65 as it waited for more research to be carried out.

"There are now three studies conducted in Britain on the AstraZenec­a vaccine which show it is as effective as other vaccines that have been approved and works for people even over the age of 80," the health agency said in a statement.

France, Belgium and Italy loosened age restrictio­ns for the AstraZenec­a vaccine earlier this week. wmr, jsi/nm (Reuters, AP,

AFP)

 ??  ?? AstraZenec­a has experience­d production delays for its vaccine
AstraZenec­a has experience­d production delays for its vaccine

Newspapers in English

Newspapers from Germany